ResApp (ASX:RAP) share price adds 4% on COVID-19 study rebate

The company's shares are continuing on yesterday's gains…

| More on:
Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ResApp Health Ltd (ASX: RAP) share price is on the move again today following yesterday's meteoric rise. The digital health company provided another positive release to the ASX today.

At the time of writing, ResApp shares are fetching for 9.3 cents apiece, up 4.49%. It's worth noting that during early morning trade, its shares reached an intraday high of 10.2 cents.

ResApp secures rebate on COVID-19 study

Investors are pushing ResApp shares higher after the company secured a cashback for its COVID-19 research program.

According to the release, ResApp advised it has received approval from AusIndustry for its application for an Advanced and Overseas Finding. In particular, this is in relation to the expenditure associated with its COVID-19 clinical studies.

The finding covers the financial years between 2021 to 2023, meaning that ResApp will be eligible for a cash rebate. This refers to the company's COVID-19 overseas research and development expenditure, thus receiving a 43.5% cashback from the Australian government.

As such, ResApp estimates that it will collect a rebate of around $820,000 for the financial year that ended 30 June 2021.

In the United States, the company is currently recruiting participants for its upcoming pilot study. The aim is to collect data to train an algorithm in identifying COVID-19 through cough sounds recorded on a smartphone.

The same participants will also be used in a second study to collect further cough sounds and data on disease progression. ResApp hopes to develop algorithms to remotely monitor patients with COVID-19.

ResApp CEO and managing director, Dr Tony Keating commented:

Our COVID-19 research program is looking at developing algorithms for screening for COVID-19 as well as helping healthcare systems better manage patients with COVID-19, including those with long COVID. This finding, recognising the need to collect COVID-19 cough samples internationally, provides us with a high degree of certainty in planning our programs.

We are very grateful to the Federal Government for their commitment to supporting research and development by Australian companies.

ResApp share price summary

Until recently, ResApp shares were trading at multi-year lows, before shooting up in September. The past month alone has netted investors a return of more than 115%, however year-to-date, is up marginally at 14%.

ResApp commands a market capitalisation of about $83.3 million and has 859 million shares on its books.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Two women jumping into the air.
Share Market News

3 ASX 200 shares that doubled in value in 2025

The ASX 200 rose by 6.8% in 2025, but as always, there were stocks that outperformed.

Read more »

Broker checking out the share price oh his smartphone and laptop.
Broker Notes

Morgans names 2 ASX shares to buy and 1 to hold

Which ones are buys and which one is a hold? Here's what you need to know.

Read more »

Ten happy friends leaping in the air outdoors.
Share Gainers

Here are the top 10 ASX 200 shares today

It was yet another positive day for Australian investors.

Read more »

red arrow representing a rise of the share price with a man wearing a cape holding it at the top
Share Market News

Goldman Sachs reveals 2026 predictions for S&P 500 and other global markets

What's the outlook?

Read more »

A man in a white coat holds a laptop in one hand and his head in the other, it's bad news.
Share Market News

Top 3 ASX 200 healthcare shares in 2025

Healthcare was the worst performing sector, as demonstrated by the comparatively mild price growth of the top 3 stocks.

Read more »

a man weraing a suit sits nervously at his laptop computer biting into his clenched hand with nerves, and perhaps fear.
Share Fallers

Why 4DMedical, Amaero, Clarity Pharmaceuticals, and Treasury Wine shares are falling today

These shares are having a poor session. What's going on?

Read more »

A woman is excited as she reads the latest rumour on her phone.
Share Gainers

Why BHP, BlueScope, Catalyst Metals, and Ryman shares are storming higher today

These shares are having a better day than most on Thursday. What's going on?

Read more »

a person stands arms outstretched on the top of a mountain with a beautiful sunrise in the sky
52-Week Highs

5 ASX 200 mining stocks including Mineral Resources and BHP shares smashing new 52-week highs today

BHP and Mineral Resources join the pack of ASX mining stocks racing to new one-year-plus highs today.

Read more »